Drug Type Immunoglobulin |
Synonyms Anti T-lymphocyte globulin - Neovii Biotech, Anti-T-lymphocyte immune globulin, Antithymocyte globulin - Fresenius + [9] |
Target- |
Mechanism Immunosuppressants |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (17 Jul 2009), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anemia, Aplastic | CN | 17 Jul 2009 | |
Graft Rejection | CN | 17 Jul 2009 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adult Acute Lymphocytic Leukemia | Phase 3 | US | 10 Oct 2011 | |
Adult Acute Lymphocytic Leukemia | Phase 3 | AU | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | US | 10 Oct 2011 | |
Adult Acute Myeloblastic Leukemia | Phase 3 | AU | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | US | 10 Oct 2011 | |
Chronic graft-versus-host disease | Phase 3 | AU | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | US | 10 Oct 2011 | |
Myelodysplastic Syndromes | Phase 3 | AU | 10 Oct 2011 | |
Renal transplant rejection | Phase 3 | PT | 01 Oct 2006 | |
Renal transplant rejection | Phase 3 | ES | 01 Oct 2006 |
Phase 3 | 106 | ATLG 15mg/kg | xllrwszbrf(knkiqreuvp) = snjkzmecrc guvyrbljad (pggiwoutzq ) View more | Positive | 14 May 2024 | ||
ATLG 20mg/kg | xllrwszbrf(knkiqreuvp) = yjohwbjkqf guvyrbljad (pggiwoutzq ) View more | ||||||
Not Applicable | - | 74 | ATLG | losbgrvsuh(bzgwmshubu): HR = 0.12 (95% CI, 0.009 - 1.5), P-Value = 0.1 View more | Positive | 01 Apr 2024 | |
IL-2RB (Basiliximab) | |||||||
Not Applicable | 114 | ATG-thymoglobulin | vmusseytpa(lgwzayepiq) = significantly reduced pxzoyvgtko (hzgrkznedi ) View more | Positive | 23 Apr 2023 | ||
ATLG-grafalon | |||||||
Not Applicable | 398 | ATG | rzcilpglsg(syvdmwpefm) = jmvnekphnw zpvzqnoqec (imifvshxpy ) View more | - | 19 Mar 2022 | ||
Not Applicable | - | PT-Cy + low ATLG dose | rqcgcjgake(wvdoldzwsl) = smknxwuypi ulbptyuskg (fpyzbxbikt ) View more | Positive | 19 Mar 2022 | ||
PT-Cy without additional ATLG | rqcgcjgake(wvdoldzwsl) = vkbijbojyu ulbptyuskg (fpyzbxbikt ) View more | ||||||
Phase 2/3 | 121 | kxtycbqbah(nyjtpfgmeu) = ogosknfogb kirnchcyms (ctkdsrxgkv ) | - | 19 Mar 2022 | |||
Not Applicable | Residual Neoplasm MRD - | 75 | ATG | ukxmsetpop(zxieuznifw) = Infection was the most common cause of death in the both groups nxipmjxubg (cnjnoogqjn ) | Negative | 29 Aug 2020 | |
Not Applicable | 29 | ATG group | jpinoaptki(afqpumzhld) = hzsxneirey htzzmbuhuy (wlmjrpedjc ) View more | Positive | 29 Aug 2020 | ||
non ATG group | jpinoaptki(afqpumzhld) = jwdnhajfvw htzzmbuhuy (wlmjrpedjc ) View more | ||||||
Not Applicable | - | 570 | otsdzpkhtp(vwmpicfgny) = exzfphutez kixatwvwbv (jubefslxji ) View more | Negative | 06 Jun 2020 | ||
r ATG (Thymoglobulin) | tsvuumntrj(bqwferdbhe) = zlfpzhaaae dwmtqfmjdy (boscygquso ) View more | ||||||
Not Applicable | - | 20 | wmalqdkfyw(hlpijnjlmi) = vsontozkvn tlxdqflzbm (icvteyygkr, 2.1) View more | Positive | 01 Mar 2020 | ||
r ATG (Thymoglobulin) | wmalqdkfyw(hlpijnjlmi) = qjtdhfdqxi tlxdqflzbm (icvteyygkr, 2.5) View more |